PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D change of 35.15% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
3110.63%
G&A change of 3110.63% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses change of 11227.11% versus flat Biotechnology costs. Walter Schloss would verify control.
11227.11%
Total costs change of 11227.11% versus flat Biotechnology costs. Walter Schloss would verify control.
26362.71%
Interest expense change of 26362.71% versus flat Biotechnology costs. Walter Schloss would verify control.
-84.19%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
-40.83%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-16129.65%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense change of 155593.20% versus flat Biotechnology. Walter Schloss would verify strategy.
-16129.65%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-12933.18%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
24.22%
Share count reduction below 50% of Biotechnology median of 0.10%. Jim Chanos would check for issues.
24.22%
Diluted share reduction below 50% of Biotechnology median of 0.10%. Jim Chanos would check for issues.